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Abstract
Sexual transmission of human immunodeficiency virus type 1 (HIV-1) most often results from productive infection by a
single transmitted/founder (T/F) virus, indicating a stringent mucosal bottleneck. Understanding the viral traits that
overcome this bottleneck could have important implications for HIV-1 vaccine design and other prevention strategies. Most
T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-
linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses. Moreover, it has been reported
that the gp120 subunits of certain transmitted Envs bind to the gut-homing integrin a4b7, possibly enhancing virus entry
and cell-to-cell spread. Here we sought to determine whether subtype C T/F viruses, which are responsible for the majority
of new HIV-1 infections worldwide, share biological properties that increase their transmission fitness, including preferential
a4b7 engagement. Using single genome amplification, we generated panels of both T/F (n=20) and chronic (n=20) Env
constructs as well as full-length T/F (n=6) and chronic (n=4) infectious molecular clones (IMCs). We found that T/F and
chronic control Envs were indistinguishable in the efficiency with which they used CD4 and CCR5. Both groups of Envs also
exhibited the same CD4+ T cell subset tropism and showed similar sensitivity to neutralization by CD4 binding site (CD4bs)
antibodies. Finally, saturating concentrations of anti-a4b7 antibodies failed to inhibit infection and replication of T/F as well
as chronic control viruses, although the growth of the tissue culture-adapted strain SF162 was modestly impaired. These
results indicate that the population bottleneck associated with mucosal HIV-1 acquisition is not due to the selection of T/F
viruses that use a4b7, CD4 or CCR5 more efficiently.
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Introduction
Mucosal transmission of HIV-1 is most often caused by a single
variant from amongst the complex viral quasispecies in the
infected donor [1–8]. After an eclipse phase of approximately two
weeks during which virus is generally not detected in the blood, the
progeny of this transmitted/founder (T/F) virus give rise to a
productive systemic infection [9–15]. At a minimum, this
significant population bottleneck selects for replication competent
viruses, most of which use CCR5 as a coreceptor, since viruses that
exclusively use CXCR4 are rarely transmitted [10,16]. Whether
other phenotypic traits are associated with enhanced mucosal
PLoS Pathogens | www.plospathogens.org 1 May 2012 | Volume 8 | Issue 5 | e1002686transmission remains uncertain, though addressing this question is
of importance because T/F viruses are the targets of vaccines,
microbicides, and pre- and post-exposure prophylaxis.
Characterization of T/F virus properties is complicated by the
challenges inherent in identifying acutely infected individuals,
generating bona fide T/F molecular clones, procuring appropriate
control viruses, obtaining sufficient numbers of samples to perform
meaningful comparisons, and developing sufficiently sensitive in
vitro assays to detect phenotypic differences that could impact
transmission fitness in vivo. Almost all studies examining viral
properties associated with mucosal transmission have focused on
the viral envelope (Env) glycoprotein, most often in the context of
viral pseudotypes [10,17–20]. In addition, most initial studies
examined viruses obtained weeks to months after infection from
relatively few transmission events [21–23]. Given the rapidity with
which HIV evolves in the face of immune pressures [24], ‘‘early’’
isolates could differ in important ways from true T/F viruses.
Nonetheless, analyses of single genome amplification (SGA)
derived T/F Env proteins and viruses have shown that mucosal
transmission is associated with CD4+ T cell tropism and CCR5
use [10,20,25,26] as well as a variety of signatures in the viral env
gene [21,27–32]. These include shorter variable loops, fewer
potential N-linked glycosylation sites (PNGs) and, in some cases,
enhanced sensitivity to neutralization by CD4 binding site (CD4bs)
monoclonal antibodies (mAbs) [20]. More recently, it has been
shown that the gp120 subunit of some Env glycoproteins can bind
to, and signal through, the integrin a4b7 that is expressed on
activated CD4+ T cells in the gut mucosa [33–35]. These findings
have been taken to suggest that these interactions play an
important role early in sexual transmission of HIV-1 [35,36].
Specifically, it has been hypothesized that genetic signatures
associated with transmission of certain subtype A and C viruses,
including the absence of some PNGs in V1/V2 and C3/V4
regions, reflect selection for Envs that exhibit strong a4b7 binding
and thus increased transmission fitness [35].
To explore the role of a4b7 interactions and other Env
properties that might impact mucosal transmission, we employed
SGA to generate a panel of T/F (n=20) and chronic control
(n=20) Env constructs from geographically-matched individuals
infected with subtype C viruses, the most prevalent HIV-1 lineage
worldwide. To examine Env phenotypes in the context of
replication competent viruses, we also produced full-length
infectious molecular clones (IMCs) for six T/F and four chronic
subtype C strains. Testing their biological activity in a variety of
functional assays, we found no differences in the efficiency with
which T/F and chronic Envs utilized CD4 or CCR5, mediated
infection of primary CD4+ T cell subsets, or were neutralized by
mAbs targeting the CD4bs. We confirmed that infection of a4b7-
expressing CD4+ T cells by the prototypic subtype B strain HIV-
1/SF162 could be partially inhibited by antibodies to a4b7 under
some conditions as previously described [33,34]. However,
saturating concentrations of a4b7 antibodies had no inhibitory
effect on infection of all-trans retinoic acid (atRA) stimulated CD4+
T cells from multiple donors by any of the T/F or chronic control
viruses, even though most of their gp120 subunits are predicted to
bind this integrin pair based on previously identified genetic
signatures [35]. These findings indicate that the ability of some
gp120 proteins to engage a4b7 may not be recapitulated by their
native Env trimers on the surface of infectious particles, and thus
suggests that interaction with this integrin pair is not critical for
mucosal HIV-1 transmission.
Results
Generation of subtype C T/F and chronic Envs
Previous studies of T/F phenotypes focused almost exclusively
on HIV-1 subtype B [10,20,37,38]. To examine the extent to
which these results are applicable to other subtypes, we focused in
this study on the transmission properties of HIV-1 subtype C. To
assess viral entry, we assembled a panel of 20 T/F Env clones, six
of which have previously been described [39]. The remaining 14
clones were derived from 13 acutely infected individuals from
South Africa and Zambia (8 males, 5 females) - nine of whom were
sampled during the earliest stages of viral infection (Fiebig stages I
and II [40]; Table 1). Plasma viral RNA was extracted, subjected
to SGA and direct amplicon sequencing, and used to infer the T/F
env sequences as previously described [12]. Consistent with earlier
findings, infection was established by one or a limited number of
viral variants. Of the 18 acutely infected individuals included in
this panel, 14 acquired a single variant, while three others were
infected with two variants and one was infected by four variants
(Table 1 and Figure S1).
To generate an appropriate control group, we obtained 20 Env
clones from individuals chronically infected with subtype C viruses
(Table 1). Seven of these have previously been described [41,42].
The remaining 13 were generated from chronically infected
individuals (11 females, 2 males) enrolled in the CHAVI 001
cohort [43]. While T/F Envs were derived from individuals of
both sexes (10 males; 10 females), chronic Envs were predomi-
nantly derived from female subjects (2 males; 18 females). To
increase the probability of identifying functional env genes, we used
SGA to generate up to 42 env gene sequences for each chronically
infected individual (Figures S2 and S3). We then constructed
phylogenetic trees to identify viruses that had undergone a recent
clonal expansion as evidenced by clusters or ‘‘rakes’’ of closely
related sequences (Figures 1, S2 and S3). We reasoned that the
common ancestor of such clonally expanded ‘‘rakes’’ would be
more likely to encode a fully functional env gene than a sequence
chosen at random from the quasispecies. To approximate this
ancestor, we cloned env amplicons whose sequences were either
identical to the consensus sequence of the corresponding rake
(n=5) or encoded an Env that differed in a single amino acid
residue (n=2). For subjects from whom none of the env amplicons
Author Summary
Most new HIV-1 infections worldwide are caused by the
sexual transmission of subtype C viruses, which are
prevalent in Asia and southern Africa. While chronically
infected individuals harbor a genetically diverse set of
viruses, most new infections are established by single
variants, termed transmitted/founder (T/F) viruses. This
raises the question whether certain viral variants have
particular properties allowing them to more efficiently
overcome the transmission bottleneck. Preferential bind-
ing of the viral envelope (Env) to the integrin a4b7 has
been hypothesized as one important feature of transmit-
ted viruses. Here, we compared Envs from subtype C
viruses that were transmitted to those that were prevalent
in chronic infections for efficiency in utilizing a4b7, CD4
and CCR5 for cell entry and replication. We found that
transmitted and chronic Envs engaged CD4 and CCR5 with
equal efficiency, and that blocking the interaction between
Env and a4b7 failed to inhibit replication of T/F as well as
control viruses. While the search for determinants of
transmission fitness remains an important goal, preferen-
tial CD4, CCR5 or a4b7 interactions do not appear to
represent distinguishing features of T/F viruses.
Entry Properties of Subtype C T/F and Chronic HIV
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PLoS Pathogens | www.plospathogens.org 3 May 2012 | Volume 8 | Issue 5 | e1002686met these criteria, the rake consensus sequence was inferred and
chemically synthesized (n=6). This same approach had also been
employed to generate the previously reported chronic Env
constructs [41,44]. Thus, all 20 chronic control Envs used in this
study were derived from clonally expanded viruses.
Functional analysis of subtype C T/F and chronic Envs
Virus pseudotypes containing a luciferase reporter gene and
bearing one of the T/F or chronic control Envs were produced in
human 293T cells and then diluted serially on NP2/CD4/CCR5
and NP2/CD4/CXCR4 cells to assess coreceptor usage and to
determine the linear range of the assay. All viral pseudotypes were
functional, leading to infection of NP2/CD4/CCR5 cells at least
100-fold above Env-negative particles. In contrast, none of the T/
F Envs and only one chronic control Env (4707.E1) mediated
entry into NP2/CD4/CXCR4 cells at levels 10-fold above
background. However, this Env did not mediate entry of GFP-
encoding pseudoviruses into primary CD4+ T cells in the presence
of the CCR5 antagonist maraviroc (data not shown). Thus, the
small amount of CXCR4-dependent infection seen in NP2/CD4/
CXCR4 cells is likely due to the over-expression of this coreceptor
and does not reflect CXCR4 use on primary cells. Importantly, all
T/F and chronic Env constructs were functional, thus validating
our methods to correctly infer T/F as well as clonally expanded
chronic control viruses.
Enhanced utilization of CD4 and CCR5 could influence virus
transmission since changes in CD4 and CCR5 expression have
been shown to impact infection by different HIV-1 strains [45–
49]. A previous study of subtype B T/F and chronic viral Envs did
not reveal differences in their utilization of CCR5 [20]. To
determine the efficiency with which the newly derived subtype C
T/F Envs utilized CD4 relative to the chronic Env controls, we
compared their ability to infect affinofile cells, a 293T cell line that
expresses CD4 and CCR5 under independently inducible
promoters [50] (Figure 2). We induced CCR5 to maximal levels
and induced CD4 to high or low expression levels (relative to
primary human CD4+ T cells; Figure 2B) prior to infection.
Infection levels of each pseudovirus in the CD4-low cells were then
expressed relative to the values obtained in the CD4-high cells
(Figure 2A). The macrophage-tropic JR-FL Env, which is known
to mediate efficient entry into cells expressing low levels of CD4
[51,52], was used as a control. Using this system, we found that
virus pseudotypes expressing T/F and clonally expanded chronic
Envs utilized CD4 with similar efficiency, while CD4 use by JR-FL
was 10-fold more efficient than most of the other pseudoviruses
(Figure 2A). These results demonstrated that the affinofile system is
sufficiently sensitive to detect differences in CD4 utilization
amongst different virus strains. Additionally, the results confirmed
earlier studies of subtype B and C viruses, which indicated that the
ability to use limiting levels of CD4 is not a major determinant of
transmission fitness [18,37].
To assess the efficiency of CCR5 use, we infected NP2/CD4/
CCR5 cells in the presence of increasing concentrations of the
CCR5 antagonist maraviroc and measured the IC50 value for each
virus. We chose this approach over the use of affinofile cells since
we have found that CCR5 expression levels cannot be controlled
with sufficient precision at intermediate concentrations of the
inducing reagent. Moreover, maraviroc titration should impact
CCR5 availability to the same degree on all cells in the population.
Therefore, maraviroc sensitivity is a surrogate for the efficiency of
CCR5 use, provided that none of the Envs tested can use CCR5
when it is bound to maraviroc [53,54]. This was true of our Env
panel; all T/F and chronic Envs examined were equally sensitive
to saturating concentrations of maraviroc with maximal percent
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exhibited similar maraviroc IC50 values (median T/F=2.22 nM;
chronic=1.67 nM; p=0.45). Thus, enhanced CCR5 utilization
efficiency does not account for the profound transmission
bottleneck of both subtype B [20] and C (Figure 2) [18] infections.
CD4+ T cell subset tropism of subtype C T/F and chronic
Envs
CD4+ T cell subsets have different activation and coreceptor
expression levels, and thus may be differentially susceptible to
infection by T/F versus chronic control viruses [55–57]. Effector
memory (TEM) and effector memory RA
+ (TEMRA) cells predom-
inate in mucosal effector sites where the transmission bottleneck
likely occurs, while central memory (TCM) and naı ¨ve cells are more
common in lymph nodes [58,59]. Therefore, an enhanced ability
to infect TEM and TEMRA cells could be linked to enhanced
mucosal transmission. To explore this, we infected primary CD4+
T cells with GFP-expressing pseudoviruses and then stained for
CCR7 and CD45RO to define naı ¨ve (CCR7+CD45RO2), TCM
(CCR7+CD45RO+), TEM (CCR72CD45RO+), and TEMRA
(CCR72CD45RO2) cells. As shown in Figure 3, we saw no
differences in the abilities of subtype C T/F and chronic control
Envs to mediate entry into these CD4+ T cell subsets. Similar to
our observations for subtype B T/F and control Envs [20], most
infected cells were TEM, but T/F Envs showed no preference for
this cell type relative to chronic control Envs.
Neutralization sensitivity of subtype C T/F and chronic
Envs
We recently reported that subtype B T/F Envs were more
sensitive than chronic Envs to the CD4bs mAbs b12 and VRC01,
and that this was attributable to increased binding of these
antibodies to the native Env trimer [20]. To determine whether
this was also true for subtype C, we performed neutralization
assays with the same antibodies. No significant differences in
neutralization sensitivity to b12, VRC01, PG9 or PG16 were
observed for T/F and chronic control Envs (Figure S4). As
expected, VRC01 generally neutralized subtype C Envs more
potently than b12 [60]. Using 10 mg/ml of b12, only five Envs
were inhibited by 50%, and the most sensitive Env was inhibited
by 83%. Using the same concentration of VRC01, 25 Envs were
inhibited by 83%, and 16 Envs were inhibited by 95%.
Nonetheless, we noted a relationship between the sensitivity to
both VRC01 and b12 and the efficiency of CD4 use. When Envs
were divided into those that used CD4 most efficiently (top 50%
regardless of whether they represented T/F or chronic controls)
and those that used CD4 least efficiently, the Envs that used CD4
efficiently were more sensitive to CD4bs (Figure 4). In contrast, no
relationship between CD4-use efficiency and neutralization
Figure 1. Clonal virus expansion in a chronically infected
subject. The phylogenetic relationships of SGA-derived 39 half genome
sequences depicting the quasispecies complexity in a chronically
infected subject are shown. Sequences highlighted in blue are
members of a recently expanded lineage, the consensus sequence of
which approximates their most recent common ancestor. The tree was
constructed using maximum likelihood methods [82]. Nodes with
bootstrap support of greater than 80% are labeled (the scale bar
represents 0.02 nucleotide substitutions per site).
doi:10.1371/journal.ppat.1002686.g001
Figure 2. T/F and chronic Envs utilize CD4 and CCR5 with
similar efficiency. (A) Efficiency of CD4 usage by T/F and chronic Env
pseudoviruses. Luciferase-encoding pseudoviruses were used to infect
affinofile cells with maximally-induced CCR5 expression and either low
or high CD4 expression. Infection of CD4-low cells was measured based
on luciferase activity and normalized to infection of CD4-high cells (y-
axis). Data shown are the mean value from three independent
experiments for all T/F and chronic Envs, each tested in triplicate; for
JR-FL the mean of each of three experiments is plotted. Grey circles
indicate poorly infectious Envs for which the CD4 use efficiency is falsely
elevated because infection of CD4-low cells was near background, as
described in the methods. The bar represents the median value of each
group with these Envs excluded. There was no significant difference in
the CD4-use efficiency between T/F and chronic envelopes (Mann-
Whitney; p=0.35). (B) CD4 expression levels from a representative flow
cytometry experiment depicting CD4 expression on minimally-induced
Affinofile cells (low), fully-induced Affinofile cells (high), and primary
human CD4+ T cells (CD4+ T). (C) Sensitivity of T/F and chronic Envs to
inhibition by maraviroc (MVC). Viral pseudotypes were used to infect
NP2/CD4/CCR5 cells in the presence of serial three-fold dilutions of the
CCR5 antagonist maraviroc. The concentration required to reduce
infection by 50% relative to no drug control (IC50) was calculated for
each pseudotype. Log MVC IC50 values are shown in the y-axis. The bar
represents the median value of each group. Higher IC50 values indicate
that more drug is required to prevent infection corresponding to more
efficient CCR5 usage, whereas lower IC50 values correspond to less
efficient CCR5 usage. No significant difference in IC50 values was found
between T/F and chronic envelope pseudotypes (Mann-Whitney;
p=0.46).
doi:10.1371/journal.ppat.1002686.g002
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PLoS Pathogens | www.plospathogens.org 5 May 2012 | Volume 8 | Issue 5 | e1002686sensitivity was observed for PG9, PG16, or purified immunoglob-
ulin pooled from five individuals infected with subtype C HIV-1
(data not shown). Thus, subtype C T/F and chronic Envs used
CD4 with similar efficiency, and there was a correlation between
CD4 utilization and sensitivity to neutralization by CD4bs mAbs.
Effect of a4b7 blockade on infection by Env pseudotypes
The gut-homing integrin a4b7 is expressed on activated CD4+
T cells in the gut [61,62] and vaginal mucosa [63] and has been
shown to bind the gp120 proteins from several recently
transmitted subtype A and subtype C viruses [35]. In contrast,
gp120 proteins from chronic viruses appear to bind a4b7 only
rarely, although the subtype B HIV-1/SF162 strain is a notable
exception [35]. Only a few studies have examined the effect of
Env-a4b7 interactions on virus replication [33,34,64]. It has been
shown that mAbs specific for a4b7 partially and transiently inhibit
infection of a4b7-positive CD4+ T cells by HIV-1/SF162 at low
inocula. Based on these studies, it has been suggested that
engagement of a4b7 may enhance HIV-1 infection, especially in
the context of mucosal transmission [35,36].
If the ability of gp120 proteins to bind a4b7 is recapitulated by
Env molecules present on virus particles, we reasoned that a4b7
engagement should enhance virus entry, especially at low
multiplicities of infection, since binding to the cell surface is a
rate-limiting step of virus infection in vitro [65,66]. If so, then
saturating levels of mAbs to a4b7 should suppress virus infection,
as has been shown for the subtype B virus strain HIV-1/SF162
[33,34]. To investigate this, we used a protocol previously
Figure 4. CD4-use efficiency correlates with CD4 binding site neutralization sensitivity. The y-axis shows sensitivity to CD4bs mAbs b12
(A) and VRC01 (B) as measured by the maximal percent inhibition (MPI) using 10 mg/ml of each mAb. Envs were divided according to their CD4-use
efficiency; those that used CD4 efficiently were more sensitive to CD4bs antibodies than Envs that used CD4 inefficiently. The bar represents the
median MPI value and p-values are from two-tailed Mann-Whitney tests.
doi:10.1371/journal.ppat.1002686.g004
Figure 3. T/F and chronic Env pseudotypes enter primary CD4+ T cell subsets with similar efficiency. Primary CD4+ T cells were infected
with GFP encoding Env pseudotypes to assess the ability of T/F and chronic Envs to mediate entry into different CD4+ T cell subsets. Three days post-
infection, cells were stained for viability as well as CD3, CD4, CD45RO and CCR7 expression [20]. In three independent experiments, cells from
different donors cells were analyzed by flow cytometry and GFP+ cells were back-gated onto memory markers to evaluate differential infection of
subsets; the average percent of infected cells falling into each subset for each Env is plotted on the y-axis. Cells were classified as central memory
(TCM: CCR7+CD45RO+), effector memory (TEM: CCR72CD45RO+), effector memory RA (TEMRA: CCR72CD45RO2), and naı ¨ve (CCR7+CD45RO2). While
TEM cells permitted the most efficient infection by Env pseudoviruses, there was no significant difference in infection efficiency between T/F and
chronic Envs in any of the subsets. The bar represents the median percentage of cells of each subset infected by T/F or chronic pseudoviruses.
doi:10.1371/journal.ppat.1002686.g003
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were stimulated with IL-2 (20 IU/ml), anti-CD3 (1.5 mg/ml) and
atRA (10 nM). Under these growth conditions, a4b7 expression
was enhanced and detected on 15–65% (median 32%) of CD4+ T
cells, predominantly on effector memory cells, from six different
donors (data not shown). One donor was non-responsive to atRA
and expressed a4b7 on only five to six percent of CD4+ T cells at
day six, so these cells were not used for subsequent experiments.
We next titrated two commercially available a4b7 mAbs, Act1
(specific for the a4b7 heterodimer) and 2B4 (specific for a4), both
of which have been shown to inhibit gp120 binding and to
suppress infection of atRA-treated CD4+ T cells by the laboratory
adapted HIV-1/SF162 strain, using concentrations previously
reported to be saturating for Act1 [33]. To determine if our
infection and inhibition conditions were sufficiently sensitive, we
used GFP reporter-expressing SF162 Env-containing pseudovirus
as the positive control. Pseudovirus expressing the JR-FL Env
served as the negative control, since the JR-FL gp120 does not
bind a4b7 [35]. We failed to detect any inhibition of infection by
either pseudovirus at a broad range of inocula using saturating
concentrations of Act1 (Figure 5). In fact, Act1 treatment
enhanced infection of SF162, JR-FL and VSV-G pseudoviruses
by approximately 30% in cells from two different donors.
However, gp120-a4b7 binding has recently been described to be
critically dependent on Env glycosylation, with high mannose
carbohydrates enhancing and complex glycans reducing a4b7
interactions [35]. We therefore reasoned that viruses derived from
primary CD4+ T cells would be physiologically more relevant,
since these cells produce Env proteins with predominantly high-
mannose carbohydrates that support a4b7 binding [67].
Effect of a4b7 blockade on replication of subtype C T/F
and chronic IMCs
To examine the impact of a4b7 blockade on the infectivity and
growth kinetics of replication competent viruses, we generated full-
length subtype C IMCs representing T/F (n=6) and chronic
control (n=4) viruses (Table 2 and Figure S3). All but three of
these had the LDI/V tripeptide motif in the V2 loop, which has
been shown to play a key role in gp120-a4b7 binding (Figure S5)
[33–35]. Moreover, the number of N-linked glycosylation sites in
the V1/V2 region of these IMCs (range from 3 to 8) was
comparable to that in gp120 proteins known to interact with a4b7
(range 3 to 9 for the strains SF162, 205F, QA203, and CAP88
[35]). Finally, all replication competent virus stocks were produced
in primary human CD4+ T cells to ensure physiologically relevant
Env glycosylation, processing and virion incorporation. Using
these reagents, we infected atRA-treated primary CD4+ T cells
with each virus strain, using a wide range (100-fold) of inocula in
the presence of saturating concentrations of Act1. In three
independent experiments, we found that Act1 consistently
inhibited replication of an SF162 Env-containing molecular clone
(NL4-3-SF162, gift from J. Arthos) at six days post-infection. This
inhibition was greatest at the lowest multiplicity of infection
(Figure 6 A and D). We also observed significant Act1-mediated
inhibition of an NL4-3 construct that encoded the subtype B Env
R3A [68], but again this was seen only at the two lowest virus
inputs (Figure 6B). No inhibition of infection and replication was
observed for YU-2 (Figure 6C), which expresses a gp120 that does
not bind a4b7 [35].
If mucosal transmission selects for viruses that interact with
a4b7, we reasoned that the replication of T/F IMCs would be
inhibited when the Env-a4b7 interaction was blocked. Our
subtype C IMC infection assays were powered to detect a 30%
or higher decrease in virus (p24 antigen) production on day six, a
time point when the largest effect on virus growth following a4b7
blockade was observed in previous experiments [34]. Two to four
ELISA measurements were performed to monitor virus produc-
tion in each of six replicate wells infected at different multiplicities
using CD4+ T cells from three different donors. At the lowest virus
inoculum, replication was undetectable in one to four of the six
replicate wells from each of the ten subtype C viruses, indicating
that virus was added at limiting dilution. Using Act1 at saturating
concentrations, we observed no significant inhibition of replication
of any subtype C virus (T/F or chronic) at any viral inoculum or
time point post-infection (Figure 7), while replication of the
positive control SF162 was reduced. In addition to Act1, we tested
the a4 integrin-specific mAb 2B4 using SF162 and three of the
subtype C viruses in CD4+ T cells from two donors and obtained
similar results: a modest and transient inhibition of SF162, but no
inhibition of the other viruses (data not shown). Finally, we tested
seven subtype B T/F IMCs [37] using cells from a single donor
and again observed no inhibition using the anti-a4b7 mAb Act1
(data not shown). Taken together, these results indicate that
blocking the integrin a4b7 does not reduce the replication of T/F
and chronic subtype C viruses in atRA-stimulated primary CD4+
T cells.
While Act1 failed to inhibit infection and/or replication by any
of 13 T/F and four chronic control viruses, it significantly
increased p24 production of five of the ten subtype C viruses (two
of six T/F and three four chronic viruses; Figure 7). This was
Figure 5. Blocking a4b7 enhances pseudovirus infection.
Infection of primary CD4+ T cells by Env pseudoviruses is depicted in
the presence and absence of Act1 to block a4b7. atRA-treated cells
were infected with GFP-expressing pseudotypes containing SF162 and
J R - F LE n v sw h o s eg p 1 2 0p r o t e i n sd oa n dd on o tb i n da4b7,
respectively, in the absence (top two panels) or presence of saturating
amounts of the a4b7 specific mAb Act1 (bottom two panels). Infected
cells were detected by GFP expression (red overlay). The presence of
Act1 resulted in slightly increased infection levels of both pseudotypes.
To confirm that saturating levels of Act1 were used, cells were stained
with fluorescently labeled Act1 before analysis. The near absence of
cells in the upper quadrants of the lower panels shows that binding of
labeled Act1 antibody was blocked by unlabeled antibody added
before virus infection.
doi:10.1371/journal.ppat.1002686.g005
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determine whether antibody binding to a4b7 could lead to
enhanced cellular activation [69] and a resulting increase in virus
production, we examined the expression of cellular activation
markers. We found that neither Act1 nor 2B4 increased the
expression of CD25, HLA-DR, Ki67, and CD69 at 1 hour, 2
Table 2. Description of T/F and chronic infectious molecular clones (IMCs).
IMC type Subject IMC name Country Risk factor
a Sex
Viral load (RNA
copies/ml)
Fiebig
stage
b
Env AA
179–181
c
V1V2
PNGs
d Reference
T/F 704010042
e CH042 South Africa HSX M 181,000 IV LDI 5 in prep
f
705010067 CH067 South Africa HSX F 639,000 I/II PDI 5 in prep
f
705010162 CH162 South Africa HSX M 13,100,000 III LDI 6 in prep
f
703010131 CH131s Malawi HSX/MSM M 411,873 I/II LDL 5 in prep
f
ZM246F
e ZM246F-10
e Zambia HSX F 10,013,800 II LDI 3 21
ZM249M
e ZM249M-1
e Zambia HSX M .2,000,000 IV LDI 6 21
Chronic 703010256 CH256 Malawi HSX F 28,066 n/a LDV 7 this study
702010432
e CH432
e Malawi HSX M 40,570 n/a LDI 8 this study
707010457
e CH457
e Tanzania HSX F 234,671 n/a VDI 6 this study
705010534
e CH534
e South Africa HSX F 63,300 n/a LDI 5 this study
aHSX=heterosexual exposure; MSM=Men who have sex with men.
bdefined in [40]; n/a=not applicable for subjects enrolled in chronic cohorts.
camino acid sequence of a4b7-binding tripeptide in V2 (positions 179–181 in HXB2).
dpotential N-linked glycosylation sites in the V1V2 region (also see Figure S5).
eEnv from subject also tested, see Table 1.
fKappes et al., manuscript in preparation.
doi:10.1371/journal.ppat.1002686.t002
Figure 6. Blocking a4b7 inhibits replication of NL4-3-SF162 and NL4-3-R3A but not YU-2. CD4+ T cells with or without Act1 pre-treatment
were infected at three different multiplicities using CD4+ T cell derived virus stock (1 ml, 10 ml and 100 ml) to initiate a spreading infection. Infections
were performed in six replicate wells, each of which was sampled at days three, six and nine. (A-C) Virus production at day six as measured by p24
content in culture supernatants is shown on the y-axis for each of six replicate wells from one of three independent experiments; uncorrected Mann-
Whitney p values are shown for comparisons of no antibody (solid symbols) versus Act1-treated (open symbols) replicate wells (bar=mean). (D)
Replication kinetics are shown for NL4-3-SF162 (mean of replicates 6 SEM is presented) at three different multiplicities of infection. Inhibition of
infection was transient and greatest at six days post infection at the lowest viral input; uncorrected Mann-Whitney p-values less than 0.05 comparing
no mAb to Act1 are marked by asterisks.
doi:10.1371/journal.ppat.1002686.g006
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PLoS Pathogens | www.plospathogens.org 8 May 2012 | Volume 8 | Issue 5 | e1002686Figure 7. Blocking a4b7 does not inhibit replication of subtype C T/F and chronic IMCs. CD4+ T cells were infected at three different
multiplicities using CD4+ T cell derived virus stock (1 ml, 10 ml and 100 ml). Virus replication was monitored by measuring p24 content in culture
supernatants; each p24 measurement was repeated two to four times. The average p24 value in each of six independent wells at six days post-
infection is plotted on the y-axis, with the bar representing the mean p24 value. Uncorrected Mann-Whitney p-values comparing no mAb to Act1 pre-
treatment are shown for each viral input. Blocking a4b7 with Act1 increased p24 production for some viruses, but had no reproducible inhibitory
effect on any T/F (A) or chronic (B) molecular clones tested, under conditions where reproducible inhibition of NL4-3-SF162 was achieved, as
previously described [34].
doi:10.1371/journal.ppat.1002686.g007
Entry Properties of Subtype C T/F and Chronic HIV
PLoS Pathogens | www.plospathogens.org 9 May 2012 | Volume 8 | Issue 5 | e1002686days, and 5 days post-treatment, nor did these antibodies lead to
an increase in CCR5 or a4b7 expression levels (Figure S6).
However, we noted increased clumping of cells in both Act1 and
2B4 treated cultures [70], which raised the possibility that the
enhanced virus production seen in some Act1-treated cultures
could be due to increased cell-to-cell viral spread. We thus used
high-speed cell imaging to examine cell-cell conjugates in CD4+ T
cell cultures from a single donor that were infected with SF162 as
well as three subtype C viruses (2 T/F and 1 chronic control) after
treatment with Act1, 2B4 or a murine IgG1 isotype-control.
Neither Act1 nor 2B4 increased expression of the high-affinity
form of LFA-1, which is known to be upregulated by a4b7
engagement of gp120 [33]. However, we noted a significant
increase in the expression of the cell-cell adhesion molecule
ICAM-1 in cells exposed to 2B4 or Act1 compared to murine
IgG1 (Figure S7A). Consistent with increased cell-cell spread,
more cell-cell conjugates were virus-positive than predicted, with
doublets being more than twice as frequently infected as singlets
(p=0.04) and triplets being more than three times as frequently
infected as singlets (p=0.06) (Figure S7B). Overall, these results
suggest that Act1- and 2B4-mediated increases in cell-cell
conjugates could facilitate more efficient spread and replication
of some viruses in the absence of increased cellular activation.
Discussion
The identification of viral traits that might enhance mucosal
transmission is an important goal for vaccine development and other
prevention strategies. A first step in characterizing such traits is the
identification of T/F viruses, while a second step is the selection of
appropriate chronic controls. Virological traits that are strongly
associated with transmission, such as CCR5 use, should be readily
identifiable when comparing T/F viruses to virtually any control
group, while identifying more subtle phenotypes will greatly depend
on the choice of control viruses, perhaps explaining discrepancies in
genetic and phenotypic transmission signatures identified by
different groups [17,18,21,23,27–30,32]. Finally, the use of in vitro
assays that recapitulate key steps in mucosal transmission are needed
toidentify properties unique to T/F viruses.Here,wehavecompiled
a relatively large panel of both Envs and IMCs representing subtype
C T/F and chronic control viruses, and developed a series of
infection assays using virus pseudotypes, replication competent
viruses, cell lines and primary human CD4+ T cells to improve our
ability to identify viral phenotypes associated with transmission.
Env glycoproteins of HIV-1 can differ significantly in the
efficiencies with which they utilize CD4 and the viral coreceptors,
which in turn can impact viral tropism [45–49]. Given the
variability in expression levels of entry cofactors on different cell
subsets as well as between individuals [71–73], it is easy to envision
several ways in which Env function could impact transmission
efficiency at the level of virus entry. To date, several genetic Env
signatures have been reported, with more compact variable loop
structures and fewer PNGs being the most frequent findings [27–
30,32]. It is possible that these genetic traits impact Env function
in ways that increase transmission fitness. However, to date no
consistent T/F phenotype has been described. Thus, it is possible
that mucosal transmission is a stochastic event where any
reasonably functional R5 or dual tropic Env can initiate a
productive infection [74]. However, it is also possible that the in
vitro assays employed thus far have failed to reveal subtler or more
transmission-specific phenotypic differences. The recent finding
that some gp120 proteins from early HIV-1 infections can bind to
the a4b7 integrin is consistent with this, although the ability of T/
F viruses to productively interact with a4b7 was not explored.
To determine whether subtype C T/F viruses, which account
for the great majority of new infections worldwide, utilize CD4 or
CCR5 with enhanced efficiency, we tested both T/F and chronic
Env constructs in pseudotyping assays. Consistent with previous
results for subtype B [20] and subtype C [18], we failed to observe
differences in both CCR5 and CD4 utilization. This is in contrast
to findings by Etemad and colleagues who reported enhanced
CCR5 utilization by Envs from individuals with chronic subtype A
infection, although only V1–V5 fragments were tested in the
context of chimeric viruses [23]. Similarly, Nawaz and colleagues
found that gp120s from three subjects acutely infected with
subtype A and C viruses bound to dodecameric but not
monomeric CD4, while gp120s from subsequent time points of
two of the same subjects bound to CD4 in both forms, suggesting
an increase in CD4 affinity in later stages of infection [35]. These
results may be specific to the particular Envs [35] or Env
fragments [23] used, or due to the fact that gp120 and particle-
associated Env trimers bind CD4 differently. In either case,
current data utilizing a large number of Env constructs strongly
suggests that the mucosal bottleneck is not the result of selective
transmission of viruses with highly efficient CD4 or CCR5 use
[17,18,20], or with increased efficiency of entry into particular
CD4+ T cells subsets [20].
We also examined whether subtype C T/F and chronic Envs
differed in their interaction with the gut homing integrin a4b7a s
recently proposed [35], although previous data are almost entirely
based on gp120 binding studies. In many ways, the a4b7
hypothesis is an attractive one. This integrin is expressed at high
levels on activated CD4+ T cells in the gut [62] and cervicovaginal
mucosa [63], both representing major sites of HIV replication
early in infection [75,76]. Moreover, intravenous administration of
an anti-a4b7 mAb in rhesus macaques prior to and during acute
infection with SIVmac239 resulted in decreased virus loads,
perhaps by inhibiting trafficking of a4b7-positive T cells to the GI
tract [77]. Finally, gp120-induced a4b7 signaling could promote
virus replication through increased cell-to-cell adhesion. However,
the ability of HIV-1 gp120 to bind a4b7 is far from universal - the
commonly studied subtype B gp120s examined to date either do
not bind to a4b7 or do so weakly, with the exception of SF162
[35]. Nonetheless, several gp120 proteins derived from early
subtype A or subtype C infections have been shown to exhibit
a4b7 binding capacity, and there is an obvious link between some
a4b7 binding properties (fewer PNGs in the V1–V4 region) and
genotypes associated with virus transmission in subtype C viruses
[21,27,35]. While monomeric gp120 binds CD4, viral coreceptors
and most broadly neutralizing antibodies, it differs from virion-
associated Env trimers in important ways. Perhaps the best
example is that numerous antibodies that bind to gp120 fail to
neutralize the cognate Env trimer, consistent with both confor-
mational differences and the fact that certain gp120 domains are
sequestered in the oligomeric molecule. Thus, a key question that
remains relatively unexplored is whether a4b7 binding by gp120
translates into an interaction by trimeric Env that influences virus
infection and spread. To address this question, we concentrated on
virus infection assays rather than gp120 binding experiments.
In our attempts to define the role of a4b7 in HIV-1
transmission, we were able to replicate a previous key finding,
namely that saturating levels of antibodies to a4b7 modestly
suppressed infection and replication by the prototypic subtype B
strain HIV-1/SF162 [33,34]. The inhibitory effects of a4b7
antibodies on SF162 infection were both transitory and most
evident when low levels of virus input were used, which is precisely
what would be expected if a4b7 functioned as an attachment
factor [34,35]. Attachment of virus particles to the host cell surface
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be overcome in part by spinoculation [65], the inclusion of
polycations that enhance viral binding [78], or the expression of
virus attachment factors such as CD209 or CD209R [79,80]. In
the case of attachment factors, their ability to enhance infection is
most pronounced when low levels of virus are used. Thus, our
finding of a partial inhibition of SF162 replication in a4b7-positive
T cells six days post infection at the lowest virus input is entirely
consistent with previous reports and shows that our assays are
sufficiently sensitive to measure the impact of a4b7 blockade on
virus infection. Despite this, we found no inhibition of any T/F or
chronic subtype B or C virus using cells from multiple donors and
levels of virus empirically determined to be barely sufficient to
establish a spreading infection. These findings are consistent with
those of Pauls and colleagues, who found that a mAb to a4 used
for the treatment of multiple sclerosis and Crohn’s disease did not
impact infection of atRA-treated CD4+ T cells by several HIV-1
strains, including two with the LDI/V tripeptide binding motif in
the V2 region [64]. Since most of our T/F and chronic viruses
possessed the a4b7-binding tripeptide motif as well as below
average numbers of PNGs in the V1/V2 region, selection bias -
i.e. the preferential inclusion of viruses that would be unlikely to
interact with a4b7 - can also be excluded. Thus, we favor the
hypothesis that not all Envs that can bind a4b7 in the form of
gp120 necessarily do so as unliganded trimers.
Our failure to detect enhancement of viral infection of human
CD4+ T cells by primary subtype B or C viruses, including T/F
viruses, due to a4b7 interaction is by no means definitive, but does
suggest that extrapolating results from gp120 bindingassays to more
complex virion infectivity studies may be misleading. It is possible
that a4b7 interactions will be more important in other types of
infection assays. In addition, we have not tested the ability of gp120
proteins derived from our viruses to bind to a4b7, although the
relevance of such findings remains uncertain unless the correspond-
ingtrimericEnvexhibits similarproperties.Ourresultsdemonstrate
the importance of using replication-competent viruses to study
properties associated with mucosal transmission. In contrast to
single-round pseudovirus assays, experiments with IMCs are
unbiased with respect to the genes that could influence fitness and
enable detection of subtle differences following multiple rounds of
replication. Thus, T/F and chronic IMCs are ideal reagents for
futurestudiesofphenotypesthat mayinfluenceHIV-1transmission.
Materials and Methods
Study subjects
This study was conducted according to the principles expressed
in the Declaration of Helsinki. It was approved by the Institutional
Review Boards of the University of Pennsylvania and Duke
University. All subjects provided written informed consent for the
collection of samples and subsequent analysis. Blood samples were
obtained from 26 subjects infected with HIV-1 subtype C. A
summary of their geographic origin and infection status is shown
in Table 1. Blood specimens were collected in acid citrate
dextrose, and plasma was separated and stored at 270uC.
Generation of T/F and chronic Envs and IMCs
The inference and cloning of T/F Envs and IMCs from SGA-
derived viral sequences has been described (Figure S1)
[10,12,13,25,37]. To ensure efficient expression of cloned subtype
C Envs for pseudotyping, the sense primer used for amplification
of the corresponding rev1-vpu-env cassette lacked the rev initiation
codon (underlined) (59-CACCGGCTTAGGCATCTCCTATAG-
CAGGAAGAA-39) [39].
Since chronic HIV-1 infections represent complex quasispecies
of genetic variants, it is impossible to predict, based on sequence
analysis alone, which members of this quasispecies are functional
and which are defective or partially defective. To generate
biologically relevant chronic controls, we thus targeted viral
variants for both Env and IMC construction that exhibited
evidence of a recent clonal expansion. Viral RNA was extracted
from the plasma of chronically infected individuals and subjected
to SGA and direct amplicon sequencing as described [12,13], with
the following modifications: 59 half genome amplification: 1
st
round sense primer 2010ForRC 59- GTCTCTCTAGGTRGAC-
CAGAT -39,1
st round antisense primer 2010Rev1C 59- AAGCA-
GTTTTAGGYTGRCTTCCTGGATG -39,2
nd round sense
primer 2010R1C 59- TAGGTRGACCAGATYWGAGCC -39
and 2
nd round antisense primer 2010Rev2C 59- CTTCTTC-
CTGCCATAGGAAAT -39;3 9 half genome: 1
st round sense
primer 07For7 59- CAAATTAYAAAAATTCAAAATTTTCGG-
GTTTATTACAG -39,1
st round antisense primer 2.R3.B6R 59-
TGAAGCACTCAAGGCAAGCTTTATTGAGGC-39,2
nd round
senseprimerVIF159-GGGTTTATTACAGGGACAGCAGAG-39
and 2
nd round antisense primer Low2C 59- TGAGGCTTAAG-
CAGTGGGTTCC -39. Thermal cycling conditions were identical
to [13] except that 60uC was used for primer annealing. Sequences
were then aligned using ClustalW [81] and subjected to phyloge-
netic analysis using PhyML [82]. Phylogenetic trees were inspected
forclustersofcloselyrelated viruses,or‘‘rakes’’,whichareindicative
of a recent clonal expansion. (Figures 1, S2 and S3). In five subjects
(Table 1), at least one env amplicon was identical in sequence to the
inferred ‘‘rake’’ consensus and thus selected for cloning using the
pcDNA3.1 Directional Topo Expression kit (Invitrogen). In two
subjects, observable ‘‘rakes’’ were limited to only two closely related
sequences, which encoded Env proteins that differed by a single
amino acid. In these cases, the amplicon that matched the within
patient consensus at this ambiguous site was cloned. In the
remaining six subjects, the consensus sequences of the clonal
expansion ‘‘rakes’’ were chemically synthesized and cloned
(designated .synR1 in Table 1). IMCs from chronically infected
subjects (CH256, CH432, CH457, and CH534) were generated
using the same approach. 39 and 59 half-genome SGA was
performed using viral RNA from subjects with evidence of clonal
expansion as determined by env sequencing. 39 and 59 half genome
sequences were used to construct neighbor joining trees (Figure S3),
and clusters of closely related sequences were selected for further
analysis. A consensus sequence of the members of such ‘‘rakes’’ was
generated using Consensus Maker (hiv.lanl.gov). 39 and 59 half
genome sequences were confirmed to be identical in their 1,040 bp
overlapping regions, chemically synthesized in fragments bordered
by unique restriction enzymes, and ligated together to construct
infectious proviral clones.
Pseudovirus production
Virus pseudotypes were produced by co-transfecting 6 mgo f
pcDNA3.1
+ containing the desired env clone with 10 mg of HIV-1
backbone (pNL43-DEnv-vpr
+-luc
+ or pNL43-DEnv-vpr
+-eGFP
(catalog no. 11100 from the NIH Aids Research and Reference
Reagent program (ARRRP) contributed by Haili Zhang, Yan
Zhou, and Robert Siliciano [83]) into 293T cells using the calcium
phosphate precipitation method. 72 h post-transfection, the
pseudovirus-containing supernatant was filtered through a
22 mm filter, aliquoted, and stored at 280uC. Pseudovirus used
to infect primary CD4+ T cells was concentrated by ultracentri-
fugation through a 20% sucrose cushion. Pelleted pseudovirus was
then resuspended in phosphate-buffered saline (PBS) in 1/100
th
the initial volume. All luciferase-encoding pseudoviral stocks were
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linear range of the assay.
Coreceptor tropism testing and cell line infections
NP2 cells stably expressing CD4 and either CCR5 (NP2/CD4/
CCR5) or CXCR4 (NP2/CD4/CXCR4) were infected with
luciferase-encoding HIV-1 pseudoviruses by spinoculation in 96-
well plates at 4506 g for 90 min at 25uC. Cells were lysed with
Brite-Glo (Promega) at 2 h post-infection and analyzed on a
Luminoskan Ascent luminometer. To assess sensitivity to cor-
eceptor inhibitor maraviroc, NP2/CD4/CCR5 cells were prein-
cubated for 30 min with saturating concentrations of the CCR5
inhibitor maraviroc (1 mM; ARRRP catalog no. 11580; [84]) or
the fusion inhibitor enfuvirtide (10 mg/ml) prior to infection. To
assess sensitivity to broadly neutralizing mAbs (HIV-1 gp120 mAb
IgG1 b12 (ARRRP catalog no. 2640) from Dennis Burton and
Carlos Barbas [85]; HIV-1 gp120 mAb VRC01 (ARRRP catalog
no. 12033) from Dr. John Mascola [60]; HIV-1 mAbs PG9 and
PG16 (ARRP catalog no. 12149 and 12150) from IAVI [86]), viral
pseudotypes were preincubated with 10 mg/ml of antibody for
1 hour at 37uC. Virus and antibody mixes were then used to infect
NP2/CD4/CCR5 cells. All NP2 cell line infections were done in
at least triplicate in at least three independent experiments using
R5-tropic JR-FL as a positive control and Env-deficient pseudo-
types as a negative control.
CD4 utilization efficiency
The ability of Env pseudoviruses to infect cells expressing low
levels of CD4 was determined using affinofile cells, which are a
modified 293T cell line that stably express CD4 and CCR5 under
the control of independently inducible promoters [50]. 5610
2 cells
were plated in each well of a 96-well plate and allowed to grow for
two days prior to infection. Cells were induced with 2 mM
ponasterone, which induces supraphysiologic levels of CCR5 thus
ensuring CD4 is the limiting factor in entry, and either 0.156 ng/
ml (CD4-low) or 5 ng/ml (CD4-high) minocycline 18 hours prior
to infection. Expression levels were monitored by quantitative
FACS analysis [57]. At the time of infection, media was exchanged
and 25 ml of luciferase-encoding pseudovirus was added. Cells
were then spinoculated at 450 g for 90 minutes. Luciferase activity
was measured three days post-infection. Each infection condition
was done in at least triplicate in each of three independent
experiments. Pseudovirus-containing vesicular stomatitis virus
glycoprotein (VSV-G) which is CD4-independent and thus infects
CD4-high and CD4-low cells equally, HIV-1 JR-CSF Env which
requires high levels of CD4, and HIV-1 JR-FL Env which can
utilize low levels of CD4 were included in all experiments as
controls [87]. To calculate CD4-use efficiency, mean relative light
units in CD4-low cells were divided by the value obtained in CD4-
high cells. The signal-to-noise ratio was higher in affinofile cells
than NP2/CD4/CCR5 cells. Nine Envs (5 T/F, 4 chronic)
infected maximally-CD4-induced afffinofile cells less than 100-fold
above background. For these Envs, we noted increased variability
across independent assays. Additionally, the ratio of CD4-high to
CD4-low infection was likely falsely elevated due to infection of
CD4-low cells at background levels. These Envs are highlighted in
Figure 2 and were excluded from subsequent analyses.
Maraviroc IC50
Maraviroc IC50 values were determined by pretreating NP2/
CD4/CCR5 cells with 11 serial 3-fold dilutions of maraviroc,
ranging from 5.9 mM to 0.1 nM, or no drug then spinoculating as
above with luciferase-encoding pseudovirus and measuring lumi-
nescence 72 h post-infection. NP2 cells were chosen for this
experiment because in the absence of CCR5 (NP2/CD4 only)
these cells are highly restrictive to infection [88]; thus entry
through potential alternative coreceptors when CCR5 is blocked
by maraviroc is negligible. IC50 was determined using Prism 4.0 to
determine the best fitting non-linear curve. Reported IC50 values
are the mean of four independent experiments, with each drug
concentration/pseudovirus condition performed in duplicate.
Primary human CD4+ T cell tropism assay
Primary human CD4+ T cells were purified by negative
selection by the University of Pennsylvania’s Human Immunology
Core. Cells were stimulated with plate-bound anti-CD3 (clone
OKT3) (eBiosciences) and anti-CD28 (clone 28.2) (BD Bioscienc-
es) and 20 U/ml recombinant interleukin-2 (IL-2) (aldesleukin,
Prometheus Laboratories) in RPMI supplemented with 10% fetal
bovine serum (FBS, Sigma-Aldrich). Three days after stimulation,
cells were transferred to 96-well V-bottom plates. Five microliters
of concentrated GFP-expressing pseudovirus was used to infect
6.7610
5 cells in triplicate by spinoculating at 1,2006g for 2 hours.
Cells were then transferred to new 24-well plates, and new
medium containing 20 U/ml IL-2 was added. Three days post-
infection, cells were stained for flow cytometry [20,54].
Flow cytometry
A total of 1–2610
6 cells from each condition were stained for
flow cytometry. Incubations were done at room temperature in
fluorescence-activated cell sorter (FACS) wash buffer (PBS, 2.5%
FBS, 2 mM EDTA). Cells were first washed in PBS, then live/
dead Aqua (Invitrogen) was added and incubated for 10 min.
Next, anti-CCR7 IgM (BD) in FACS wash buffer was added and
incubated for 30 min. Cells were then washed in FACS wash
buffer before staining with anti-CD3–Qdot 655 (Invitrogen), anti-
CD4–Alexa Fluor 700 (BD), anti-CD45RO–phycoerythrin (PE)-
Texas Red (Beckman Coulter), and anti-IgM–PE (Invitrogen) for
30 min. Cells were then washed in FACS wash buffer and
resuspended in 1% paraformaldehyde (PFA). Samples were run on
an LSRII (BD) instrument and analyzed with FlowJo 8.8.6
(Treestar). Cells were gated as follows: singlets (FSC-A by FSC-H),
then live cells (SSC-A by live/dead), then lymphocytes (SSC-A by
FSC-A), then CD3
+ cells (SSC-A by CD3), then memory markers
(CCR7 by CD45RO).
To examine activation of cells treated with Act1, 2B4, isotype
control murine IgG1, or no antibody, cells were pretreated with
33 nm of the specified antibody for 1 hour, 2 days, or 5 days. At
each time point, 1610
6 cells were washed in PBS, then live/dead
Aqua was added for 10 minutes. Anti-CCR5-PE (BD), anti-CD4-
PerCP-Cy5.5, anti-CD25-APC-Cy7, anti-HLA-DR-PE-Cy7, anti-
a4b7-Alexa Fluor 680 (clone Act1) and anti-CD45RO-TexasRed-
PE were added in FACS wash buffer for 30 minutes. Cells were
then washed in FACS wash buffer and treated with cytofix/
cytoperm buffer (BD) for 17 minutes. Anti-CD3-V450, anti-
CD69-APC, and anti-Ki67-FITC in perm/wash buffer were
added and incubated for 1 hour at room temperature. Cells were
washed in perm/wash buffer, fixed in 0.1% paraformaldehyde,
run on an LSRII instrument and data was analyzed with FlowJo.
Live cells expressing CD3 and CD4 were analyzed for expression
of activation markers.
Production of HIV in primary CD4+ T cells
Replication competent viral stocks were generated by transfect-
ing a 10 cm dish 30% confluent with 293T cells with 6 mg of IMC
DNA. Virus was harvested 72 hours post-transfection and filtered
through a 45 micron low protein binding filter. 293T-derived HIV
was then used to infect stimulated human CD4+ T cells. 18 hours
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derived virus. CD4+ T cell derived HIV was then harvested 11
days post infection, filtered through a 45 micron filter, aliquoted
and frozen at 280uC. p24 antigen concentration of viral stocks
was assessed by Alliance ELISA and high sensitivity alphaLISA
(Perkin Elmer); these methods were in good agreement for all
IMCs tested.
Infection assay to assess effect of a4b7 blockade
Freshly isolated human CD4+ T cells purified by negative
selection were stimulated with 1.5 mg/ml anti-CD3 clone OKT3,
20 units/ml IL-2, and 10 nM atRA. atRA was resuspended in
DMSO, filter sterilized, aliquoted in the dark, and immediately
frozen at 280uC for no longer than one month. 24 hours after
stimulation, media was removed, and new media with IL-2 and
atRA was added. Media was changed and new IL-2 and atRA
were added every two to three days. Efforts were made to precisely
follow previously reported methods [33,34]. Cells were infected six
days post-stimulation for both pseudotype and replication
competent HIV infection. Cells were pre-treated for 1 hour with
33 nM Act1 (an a4b7 heterodimer specific mAb; ARRRP catalog
no. 11718 from Dr. A. A. Ansari [89]) at 37uC prior to infection.
a4b7 expression and saturating mAb blockade was confirmed on
the day of infection by flow cytometry. a4b7 expression was
determined with Alexa Fluor 680-conjugated Act1 (Invitrogen).
GFP-expressing pseudotype infections were performed as de-
scribed above. SF162 and JR-FL pseudovirions were used as
positive and negative controls, respectively [35]. For infections
with replication competent HIV, virus made in CD4+ T cells was
used to limit potentially non-physiologic properties of 293T-
derived HIV. 2610
5 stimulated atRA-treated CD4+ T cells were
plated in 100 ml per well of a 96-well plate. After incubation with
Act1 or media only, 100 ml of CD4+ T cell-derived virus was
added at a neat, 1:10, or 1:100 dilution. Cells were infected for five
hours at 37uC without spinoculation and then cells were washed
four times to remove unbound HIV. Three, six, and nine days
post-infection, media was changed and p24 antigen concentration
was assessed in the supernatant using an alphaLISA high
sensitivity kit (Perkin Elmer) read on a Synergy H4 plate reader
(BioTek instruments). Either four or six replicate wells were used
per condition, and each alphaLISA measurement was performed
2–4 times. AlphaLISA assays were performed in 25 ml volume in
384 well plates. Each plate contained an internal standard curve
ranging four orders of magnitude with each standard concentra-
tion repeated in eight wells. The lower limit of detection for most
assays ranged between 3 and 10 pg p24 per mL.
High-speed cell imaging
Purified CD4+ T cells were treated with atRA, anti-CD3, and
IL-2, and infected as described for a4b7 blocking experiments.
Nine days post infection, cells exposed to 10 ml of NL4-3-SF162,
ZM249, CH162, CH256, and mock infected were pooled from six
replicate wells, washed in PBS and then FACS wash buffer. Anti-
CCR5-PE-Cy7, anti-CD54 (ICAM-1)-PE-Cy5, anti-LFA-1-PE
(clone MEM-148), and anti-a4b7-Alexa Fluor 680 (clone Act1)
were added in FACS wash buffer and allowed to incubate for
30 minutes. Cells were then washed in FACS wash buffer and
treated with cytofix/cytoperm buffer for 17 minutes. Anti-Gag-
FITC (clone KC-57) was added for 1 hour. Cells were fixed in 1%
paraformaldehyde and DAPI was added 30 minutes prior to
analysis. Samples were run on an ImageStream IS100 equipped
with two cameras and 405, 488, and 658 nm excitation lasers. At
least 20,000 images were collected per condition, and the upper
limit of images classified as cells was set to 600 pixels to allow
collection of cell-cell conjugates. Cells were gated as follows:
singlets, doublets, and triplets (DAPI by brightfield area), then
Gag+ (Gag intensity by Gag median pixel). Gag positivity was
gated such that the percent of mock-infected Gag+ cells was equal
in singlet, doublet, and triplet populations. A single Gag-
expressing cell was sufficient for a doublet or triplet image to be
considered Gag+, as confirmed by visual inspection of Gag+
images. LFA-1 and ICAM-1 expression were analyzed on
nucleated (DAPI+), focused (brightfield gradient root mean
square-high), singlets (brightfield aspect ratio ,1) to ensure that
all analyzed images were of high quality.
Statistical analysis
To test the hypothesis that T/F Envs as a group were different
from chronic Envs in various functional measures, we used two-
tailed Mann-Whitney tests. To test the hypothesis that Act1
treatment inhibited viral replication in CD4+ T cells, we again
used two-tailed Mann-Whitney tests comparing the six biological
replicates with and without Act1 treatment for each virus. No
attempts were made to correct for multiple testing, largely because
Act1 treatment did not have the expected effect on T/F viruses.
Because six values from each group were compared, the minimum
uncorrected p-value was 0.002. Applying the conservative
Bonferroni correction would render all comparisons insignificant
(a level of 0.05 divided by 39 tests=0.001). Thus, we conclude
that Act1 inhibits or enhances only when multiple input levels of
the same virus show a consistent effect. To determine if cell-cell
conjugates were infected more than expected by chance, the
percent of Gag+ doublets was compared in a paired t-test to
double the percent Gag+ singlets, and the percent of Gag+ triplets
was compared to triple the percent Gag+ singlets.
Nucleotide accession numbers
All newly obtained HIV-1 sequences have been submitted to
GenBank and are available under accession numbers listed in
Table S1.
Supporting Information
Figure S1 Inference of T/F env sequences. Maximum
likelihood trees of SGA-derived env sequences (left) and corre-
sponding Highlighter plots (right) are shown for eight subjects
acutely infected with HIV-1 subtype C viruses. Highlighter plots
depict sequence alignments (Highlighter v2.1.1; hiv.lanl.gov); tick
marks indicate differences compared to the top sequence (red, T;
green, A; blue, C; orange, G; grey, gap). The trees were
constructed using PhyML [82]. Except for in panel A
(bar=0.005 substitutions per site), the scale bar represents a
single nucleotide substitution. Sequences chosen for cloning are
marked with an arrow. In most subjects, a single low diversity
lineage was observed (B, D, E, F, H), indicating infection with a
single T/F virus. Subjects 20258279 (A) and 21197826 (C) were
infected with four and two T/F viruses, respectively. The tree from
subject 19157834 (G) shows a lineage with at least four shared
mutations, which likely represents a second closely related T/F
virus (a single sequence highlighted in green exhibits GRA
hypermutation). In all cases, the cloned envs represent unambig-
uously determined T/F viruses. GenBank accession numbers for
the env sequences are listed in Table S1.
(EPS)
Figure S2 Identification of clonally expanded viral
lineages in chronically infected individuals. The phyloge-
netic relationships of SGA-derived env sequences depicting the
quasispecies complexity in chronically infected subjects are shown
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[82]. Asterisks indicate bootstrap support of greater than 80% (the
scale bar represents 0.02 substitutions per site). Sequences
highlighted in blue indicate a recently expanded viral lineage,
the consensus sequence of which approximates their most recent
common ancestor. Red arrows denote env amplicons chosen for
cloning (A, B, D, F, G, H, J) while red lines indicate ‘‘rakes’’ used
to infer consensus sequences for chemical synthesis (C, E, I).
GenBank accession numbers for the env sequences are listed in
Table S1.
(EPS)
Figure S3 Construction of chronic IMCs from overlap-
ping 59 and 39 half genome sequences. The phylogenetic
relationships of SGA-derived 59 and 39 half genome sequences
depicting the quasispecies complexity in chronically infected
subjects are shown. Trees composed of 59 (A, C, E, G) and 39
(B, D, F, H) half genome sequences were constructed using
maximum likelihood methods [82]. Sequences highlighted in blue
were used to generate half genome consensus sequences for each
subject (A and B 703010256, C and D 702010432, E and F
707010457, H and G 705010534) that were confirmed to be
identical in sequence in the region of overlap then chemically
synthesized to generate full-length IMCs. Asterisks indicate
bootstrap support of greater than 80% (the scale bar represents
0.02 substitutions per site). GenBank accession numbers for the 59
and 39 half genome sequences are listed in Table S1.
(EPS)
Figure S4 Neutralization of T/F and chronic Envs. The
maximal percent inhibition (MPI) of 10 mg/ml of b12, VRC01,
PG9 and PG16 on infection by T/F and chronic Env
pseudoviruses is shown on the y-axis. The bar represents the
median MPI. Numbers on the top indicate two-sided Mann-
Whitney p-values comparing T/F to chronic Envs for each mAb.
(EPS)
Figure S5 Alignment of V1V2 Env protein sequences. An
alignment of the first and second variable regions of the HIV-1
Env glycoprotein (HXB2 gp120 residues 131–196) is shown for
previously described a4b7-reactive gp120s as well as T/F and
chronic IMCs. Asparagine residues predicted to be glycosylated
are shown in red. The a4b7 binding-site (consensus LDV/I; HxB2
residues 179–181) is highlighted in grey. Gaps, shown as dashes,
were introduced to optimize the alignment.
(EPS)
Figure S6 Act1 and 2B4 do not affect the activation
profile of cells compared to a murine isotype control.
Cells from three different donors were treated with Act1 (red) or
2B4 (blue) as well as a murine IgG1 control (open) for one hour
(A), two days (B), or five days (C), and analyzed for markers of
cellular activation, including CD25, HLA-DR, Ki67, and CD69.
The expression of CCR5 and a4b7 was also measured. The
percent of live CD4+ T cells expressing each marker is shown on
the y-axis. No significant differences were observed comparing
Act1 or 2B4 treated cells to IgG1, except for decreased a4b7
expression at day five, which reflects decreased detection due to
blocking with unlabeled Act1.
(EPS)
Figure S7 Cell-to-cell adhesion and infection analysis.
High-speed imaging of single cells and cell aggregates was
performed using an ImageStream IS100 cytometer. (A) Treatment
with Act1 (red) or 2B4 (blue) increased the percent of singlet cells
expressing the cell adhesion molecule ICAM-1 (y-axis) relative to a
murine isotype (IgG, open) control (p=0.04; Mann-Whitney).
Each point represents cells from the same donor infected with a
different virus, or mock infected; the bar indicates the group
median. (B) Cells were gated based on DNA content and size into
individual cells (singlets), two cells in contact (doublets) and three
cells in contact (triplets). The percent of singlets, doublets, and
triplets infected after exposure to different viruses is shown on the
y-axis. Cell infection was determined based on Gag (p24) antigen
expression compared to mock-infected control. Cell conjugates
contained more infected cells than expected by chance, suggesting
enhanced cell-to-cell spread (doublets, p=0.04; triplets, p=0.06;
two-sided paired T-test).
(EPS)
Table S1 GenBank accession numbers of sequences
generated for this study.
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